ESCII–PIVAC meeting “Recent advances in cancer immunotherapy with an emphasis on cancer vaccines” held in Athens, 9–11 October 2008

2009 ◽  
Vol 59 (4) ◽  
pp. 635-640
Author(s):  
Viktor Umansky ◽  
Barbara-ann Guinn
Keyword(s):  
Cancer Immunotherapy ◽  
Cancer Vaccines ◽  
Recent Advances

scholarly journals Recent Progress in Dendritic Cell-Based Cancer Immunotherapy

Cancers ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 2495
Author(s):  
Kazuhiko Matsuo ◽  
Osamu Yoshie ◽  
Kosuke Kitahata ◽  
Momo Kamei ◽  
Yuta Hara ◽  
...  
Keyword(s):  
Cancer Immunotherapy ◽  
Immune Checkpoint ◽  
Targeted Delivery ◽  
Cancer Vaccines ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Host Immune Responses ◽  
Near Future ◽  
Identification And Characterization

Cancer immunotherapy aims to treat cancer by enhancing cancer-specific host immune responses. Recently, cancer immunotherapy has been attracting much attention because of the successful clinical application of immune checkpoint inhibitors targeting the CTLA-4 and PD-1/PD-L1 pathways. However, although highly effective in some patients, immune checkpoint inhibitors are beneficial only in a limited fraction of patients, possibly because of the lack of enough cancer-specific immune cells, especially CD8+ cytotoxic T-lymphocytes (CTLs), in the host. On the other hand, studies on cancer vaccines, especially DC-based ones, have made significant progress in recent years. In particular, the identification and characterization of cross-presenting DCs have greatly advanced the strategy for the development of effective DC-based vaccines. In this review, we first summarize the surface markers and functional properties of the five major DC subsets. We then describe new approaches to induce antigen-specific CTLs by targeted delivery of antigens to cross-presenting DCs. In this context, the chemokine receptor XCR1 and its ligand XCL1, being selectively expressed by cross-presenting DCs and mainly produced by activated CD8+ T cells, respectively, provide highly promising molecular tools for this purpose. In the near future, CTL-inducing DC-based cancer vaccines may provide a new breakthrough in cancer immunotherapy alone or in combination with immune checkpoint inhibitors.

Recent Advances in Cell Membrane‐Derived Biomimetic Nanotechnology for Cancer Immunotherapy

2021 ◽  
pp. 2002081
Author(s):  
Faisal Raza ◽  
Hajra Zafar ◽  
Shulei Zhang ◽  
Zul Kamal ◽  
Jing Su ◽  
...  
Keyword(s):  
Cell Membrane ◽  
Cancer Immunotherapy ◽  
Recent Advances

Recent advances in breast cancer immunotherapy: The promising impact of nanomedicines

Life Sciences ◽  
2021 ◽  
Vol 271 ◽  
pp. 119110
Author(s):  
Nastaran Hashemzadeh ◽  
Mitra Dolatkhah ◽  
Khosro Adibkia ◽  
Ayuob Aghanejad ◽  
Mohammad Barzegar-Jalali ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Immunotherapy ◽  
Recent Advances

Tumor Microenvironment-Triggered In-Situ Cancer Vaccines with Dual Immunogenic Cell Death Inductions for Elevated Antitumor and Antimetastatic Therapy

Nanoscale ◽  
2021 ◽  
Author(s):  
Jun Lin ◽  
Binbin Ding ◽  
Pan Zheng ◽  
Dong Li ◽  
Meifang Wang ◽  
...  
Keyword(s):  
Cell Death ◽  
Tumor Microenvironment ◽  
Immune Responses ◽  
Cancer Immunotherapy ◽  
Cancer Vaccines ◽  
High Specificity ◽  
The Body ◽  
Immunogenic Cell Death ◽  
Specific Antigens

Cancer vaccine is to make tumor-specific antigens into vaccines, which then are injected back into the body to activate immune responses for cancer immunotherapy. Despite the high specificity and therapeutic...

scholarly journals Engineered drug-loaded cells and cell derivatives as a delivery platform for cancer immunotherapy

2021 ◽  
Author(s):  
Lu Wang ◽  
Jinyao Liu
Keyword(s):  
Cancer Immunotherapy ◽  
Intact Cells ◽  
Recent Advances ◽  
Delivery Platform

Recent advances in improving cancer immunotherapy have been summarized with a focus on using functionalized intact cells and cell derivatives.

scholarly journals Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies

2014 ◽  
Vol 14 (12) ◽  
pp. 1769-1781 ◽  
Author(s):  
Ira Surolia ◽  
James Gulley ◽  
Ravi A Madan
Keyword(s):  
Cancer Vaccines ◽  
Recent Advances ◽  
Therapeutic Cancer Vaccines

scholarly journals Recent Advances in Cancer Vaccines: An Overview

2008 ◽  
Vol 39 (2) ◽  
pp. 73-80 ◽  
Author(s):  
K. Itoh ◽  
A. Yamada ◽  
T. Mine ◽  
M. Noguchi
Keyword(s):  
Cancer Vaccines ◽  
Recent Advances

Recent advances on the immunomodulatory effects of IFN-α: Implications for cancer immunotherapy and autoimmunity

Autoimmunity ◽  
2010 ◽  
Vol 43 (3) ◽  
pp. 204-209 ◽  
Author(s):  
Paola Rizza ◽  
Franca Moretti ◽  
Filippo Belardelli
Keyword(s):  
Cancer Immunotherapy ◽  
Immunomodulatory Effects ◽  
Recent Advances

Results of the safety evaluation of cancer vaccines dealing with novel targets for cancer immunotherapy

2016 ◽  
Vol 259 ◽  
pp. S151-S152
Author(s):  
A. Mancebo ◽  
A.M. Bada ◽  
A. Casacó ◽  
B. González ◽  
A. León ◽  
...  
Keyword(s):  
Cancer Immunotherapy ◽  
Cancer Vaccines ◽  
Safety Evaluation ◽  
Novel Targets
Sign in / Sign up

Export Citation Format

Share Document